Immix Biopharma, Inc. IMMX Debt Issuance Costs
Debt Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentOfFinancingAndStockIssuanceCosts.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s debt issuance costs?
- Immix Biopharma, Inc. (IMMX) reported debt issuance costs of $71.09K in Q1 2026.
- How has Immix Biopharma, Inc.'s debt issuance costs changed year-over-year?
- Immix Biopharma, Inc.'s debt issuance costs increased by 107.6% year-over-year, from $34.25K to $71.09K.
- What is the long-term trend for Immix Biopharma, Inc.'s debt issuance costs?
- Over 2 years (2022 to 2025), Immix Biopharma, Inc.'s debt issuance costs has grown at a 351.4% compound annual growth rate (CAGR), from $6.72K to $137K.
- What does debt issuance costs mean?
- Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.